Clinical Outcome of Subclinical Cushing's Syndrome After Surgical and Conservative Treatment
Overview
Authors
Affiliations
Subclinical Cushing's syndrome (SCS), a subtle cortisol hypersecretion from an adrenal tumor, may be a common adrenal disease. However, the cardiovascular prognosis and the optimal surgical and conservative treatment in SCS remain elusive. The present study was undertaken to evaluate the prevalence of cardiovascular risk factors in 16 SCS cases, their relationships to cortisol secretory activities, and the clinical outcome after surgical and medical treatment. The prevalence of hypertension, impaired glucose tolerance (IGT), diabetes mellitus (DM), dyslipidemia and obesity in our SCS cases were 56%, 50%, 50%, and 19%, respectively, and 75% of cases were associated with two or more cardiovascular risk factors. In our series, 24-h urinary free-cortisol excretion showed a significant positive correlation with HbA1c and a negative correlation with high-density lipoprotein-cholesterol, but no correlation with age, body mass index, blood pressure or glycemic and lipid profile was found. Eight cases underwent unilateral adrenalectomy (operated (OP) group); the remaining eight cases were a conservative-treatment group (non-OP group). The number of cardiovascular risk factors decreased significantly in the OP group, but not in the non-OP group. In terms of differential changes in risk factors between the groups, more significant improvements of hypertension, dyslipidemia and IGT/DM were observed in the OP group than in the non-OP group. In conclusion, the present study showed the increased prevalence of cardiovascular risk factors in SCS patients with mild hypercortisolism related to impaired glucose/lipid metabolism. Adrenalectomy decreased accumulated cardiovascular risk factors in certain SCS patients, suggesting the possible involvement of mild hypercortisolism in the development of cardiovascular risk factors in SCS.
Evaluation of adrenal tumors and analysis of the metabolic profile of patients with incidentaloma.
Montalvao P, Mangueira I, Alves G, Cordeiro J, Costa M, Ravanini G Rev Col Bras Cir. 2025; 51():e20243685.
PMID: 39841720 PMC: 11702972. DOI: 10.1590/0100-6991e-20243685-en.
Ren X, Nan M, Zhang X Front Endocrinol (Lausanne). 2024; 15():1399311.
PMID: 39086899 PMC: 11288901. DOI: 10.3389/fendo.2024.1399311.
Khadembashiri M, Mohseni S, Harandi H, Pejman Sani M, Khadembashiri M, Atlasi R Front Endocrinol (Lausanne). 2024; 15:1374711.
PMID: 38808111 PMC: 11131104. DOI: 10.3389/fendo.2024.1374711.
An Overlooked Disease: Minimal Autonomous Cortisol Secretion (MACS). A Narrative Review.
Farah S, Nasr L, Eid Fares J Endocr Metab Immune Disord Drug Targets. 2024; 24(13):1518-1524.
PMID: 38686896 DOI: 10.2174/0118715303266569231129101847.
Lin D, Lin J, Hu X, Liu Y, Zhang J, Zhang L Transl Androl Urol. 2021; 10(1):426-437.
PMID: 33532330 PMC: 7844482. DOI: 10.21037/tau-20-1108.